Log in

NASDAQ:HSKA - Heska Stock Price, Forecast & News

+4.86 (+5.12 %)
(As of 02/26/2020 08:00 AM ET)
Today's Range
Now: $99.77
50-Day Range
MA: $101.45
52-Week Range
Now: $99.77
Volume97,600 shs
Average Volume45,412 shs
Market Capitalization$781.20 million
P/E Ratio212.28
Dividend YieldN/A
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps. Read More…

Industry, Sector and Symbol

Industry Diagnostic substances
Current SymbolNASDAQ:HSKA



Sales & Book Value

Annual Sales$127.45 million
Cash Flow$2.18 per share
Book Value$16.13 per share


Net Income$5.85 million


Market Cap$781.20 million
Next Earnings DateN/A
OptionableNot Optionable

Receive HSKA News and Ratings via Email

Sign-up to receive the latest news and ratings for HSKA and its competitors with MarketBeat's FREE daily newsletter.

Heska (NASDAQ:HSKA) Frequently Asked Questions

What is Heska's stock symbol?

Heska trades on the NASDAQ under the ticker symbol "HSKA."

How were Heska's earnings last quarter?

Heska Corp (NASDAQ:HSKA) released its quarterly earnings data on Tuesday, February, 25th. The medical research company reported ($0.18) EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.03 by $0.21. Heska had a return on equity of 3.17% and a net margin of 3.15%. View Heska's Earnings History.

What guidance has Heska issued on next quarter's earnings?

Heska updated its FY 2020 Pre-Market earnings guidance on Tuesday, February, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $135-145 million, compared to the consensus revenue estimate of $141.76 million.

What price target have analysts set for HSKA?

8 Wall Street analysts have issued twelve-month target prices for Heska's shares. Their forecasts range from $68.00 to $107.00. On average, they expect Heska's stock price to reach $88.80 in the next year. This suggests that the stock has a possible downside of 11.0%. View Analyst Price Targets for Heska.

What is the consensus analysts' recommendation for Heska?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heska in the last year. There are currently 7 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Heska.

What are Wall Street analysts saying about Heska stock?

Here are some recent quotes from research analysts about Heska stock:
  • 1. According to Zacks Investment Research, "Heska Corporation sells advanced veterinary diagnostic and specialty products. Heska's state-of-the-art offerings include blood testing instruments and supplies, digital imaging products, software and services, data services, allergy testing and immunotherapy, and single-use offerings such as in-clinic diagnostic tests and heartworm preventive products. The Company's core focus is on the canine and feline markets where it strives to provide high value products and unparalleled support to veterinarians. " (11/15/2019)
  • 2. Canaccord Genuity analysts commented, "We view this financing as overdue" as the company had been operating for some time at a cash balance hovering around $10 million. We trim our out year revenue and earnings estimates as we exercise more conservatism on Heska’s top line growth, and we expect a higher level of spending to help return the company to growth, following ~3 years of missing expectations. We are cautiously optimistic to see Heska deliver on its growth initiatives, however, our near-term expectations are tempered until we see evidence of stronger commercial execution. While we trim our estimates and price target to $75 (from $95), we are sticking with our BUY rating in hopes we see progress on new product and geographic expansion as we look out to 2020. Convertible notes." (9/12/2019)

Has Heska been receiving favorable news coverage?

News headlines about HSKA stock have trended very negative recently, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Heska earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave headlines about the medical research company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Heska.

Who are some of Heska's key competitors?

What other stocks do shareholders of Heska own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Heska investors own include Broadcom (AVGO), Biogen (BIIB), Netflix (NFLX), Western Digital (WDC), Exelixis (EXEL), Gilead Sciences (GILD), Micron Technology (MU), Exxon Mobil (XOM), AT&T (T) and Amgen (AMGN).

Who are Heska's key executives?

Heska's management team includes the folowing people:
  • Mr. Kevin S. Wilson, CEO, Pres & Director (Age 47)
  • Mr. Jason A. Napolitano, COO & Chief Strategist (Age 51)
  • Ms. Catherine I. Grassman CPA, VP, Chief Accounting Officer & Corp. Controller (Age 43)
  • Dr. Nancy Wisnewski, Exec. VP of Diagnostic Operations & Product Devel. (Age 56)
  • Mr. Jason D. Aroesty, Exec. VP of International Diagnostics (Age 44)

Who are Heska's major shareholders?

Heska's stock is owned by many different of institutional and retail investors. Top institutional investors include Fred Alger Management LLC (13.32%), Standard Life Aberdeen plc (3.78%), Riverbridge Partners LLC (3.70%), State Street Corp (3.63%), FMR LLC (3.05%) and SG Capital Management LLC (2.33%). Company insiders that own Heska stock include Bonnie J Trowbridge, G Irwin Gordon, Jason A Napolitano, Kevin S Wilson, Nancy Wisnewski, Rod Lippincott, Scott Humphrey, Steve Asakowicz and Steven M Eyl. View Institutional Ownership Trends for Heska.

Which major investors are selling Heska stock?

HSKA stock was sold by a variety of institutional investors in the last quarter, including SG Capital Management LLC, Standard Life Aberdeen plc, SG Americas Securities LLC, State Street Corp, Grace & White Inc. NY, Jane Street Group LLC, Citigroup Inc. and US Bancorp DE. View Insider Buying and Selling for Heska.

Which major investors are buying Heska stock?

HSKA stock was acquired by a variety of institutional investors in the last quarter, including Johanson Financial Advisors Inc., Public Sector Pension Investment Board, Aviva PLC, Russell Investments Group Ltd., Geode Capital Management LLC, Great West Life Assurance Co. Can, Fred Alger Management LLC and California Public Employees Retirement System. View Insider Buying and Selling for Heska.

How do I buy shares of Heska?

Shares of HSKA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Heska's stock price today?

One share of HSKA stock can currently be purchased for approximately $99.77.

How big of a company is Heska?

Heska has a market capitalization of $781.20 million and generates $127.45 million in revenue each year. The medical research company earns $5.85 million in net income (profit) each year or $1.42 on an earnings per share basis. Heska employs 347 workers across the globe.View Additional Information About Heska.

What is Heska's official website?

The official website for Heska is http://www.heska.com/.

How can I contact Heska?

Heska's mailing address is 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO, 80538. The medical research company can be reached via phone at 970-493-7272 or via email at [email protected]

MarketBeat Community Rating for Heska (NASDAQ HSKA)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  311 (Vote Outperform)
Underperform Votes:  344 (Vote Underperform)
Total Votes:  655
MarketBeat's community ratings are surveys of what our community members think about Heska and other stocks. Vote "Outperform" if you believe HSKA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HSKA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/26/2020 by MarketBeat.com Staff

Featured Article: Correction

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel